Amplify Weight Loss Drug & Treatment ETF
THNR
2 hedge funds and large institutions have $395K invested in Amplify Weight Loss Drug & Treatment ETF in 2025 Q4 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 0 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
6.07% less ownership
Funds ownership: 19.91% → 13.84% (-6.1%)
35% less capital invested
Capital invested by funds: $606K → $395K (-$211K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCA
Cravens & Co Advisors
Cookeville,
Tennessee
|
+$370K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$555K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$51.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CCA
1
Cravens & Co Advisors
Cookeville,
Tennessee
| $390K | +$370K | +15,023 | New |
|
|
GFA
2
Godfrey Financial Associates
Glenmont,
New York
| $5.07K | +$4.94K | +201 | New |
|
|
3
Jane Street
New York
| – | -$555K | -23,704 | Closed |
|
|
4
UBS Group
Zurich,
Switzerland
| – | -$51.1K | -2,184 | Closed |
|
THNR Hedge Fund Activity: Q4 2025 in Review
2 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Amplify Weight Loss Drug & Treatment ETF (THNR) for Q4 2025, worth a combined $395K — down 35% from $606K a quarter earlier.
Fund positioning in THNR was balanced in Q4 2025: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was Cravens & Co Advisors, opening a new position worth an estimated $370K. The largest seller was Jane Street, exiting entirely with an estimated $555K sold.
- 2 institutional investors held Amplify Weight Loss Drug & Treatment ETF (THNR) as of Q4 2025, unchanged from Q3 2025.
- Funds reported $395K of Amplify Weight Loss Drug & Treatment ETF stock for Q4 2025, down 35% quarter-over-quarter.
- 2 funds opened new Amplify Weight Loss Drug & Treatment ETF positions in Q4 2025 and 2 closed out, a net change of 0 holders.
- The largest Amplify Weight Loss Drug & Treatment ETF buyer in Q4 2025 was Cravens & Co Advisors, an estimated $370K added.
- The largest Amplify Weight Loss Drug & Treatment ETF seller in Q4 2025 was Jane Street, an estimated $555K sold.
Based on aggregated 13F filings for Q4 2025.